PODKhODY K TERAPII ARTERIAL'NOY GIPERTENZII U PATsIENTOV S KhRONIChESKOY OBSTRUKTIVNOY BOLEZN'Yu LEGKIKh


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the features of antihypertensive therapy in patients with chronic obstructive pulmonary disease (COPD) and arterial hypertension (AH). It is emphasized that the choice of therapy for COPD patients with AH is associated with serious difficulties, since the combination of these conditions leads to a significant burdening by each of diseases, and antihypertensive drugs, bronchodilators, and hormones in some cases have side effects burdening comorbid disease. It is noted that five major classes of antihypertensive drugs should be used for the treatment of AH in combination with COPD with certain constraint: ACE inhibitors, angiotensin receptor AT 1 blockers, calcium channel blockers, β-blockers and diuretics. Typically, a combination of 2-3 or more medications is used. The most effective and safe treatment for patients with AH and COPD is a combination of ARB with a calcium channel blocker or thiazide diuretic.

Full Text

Restricted Access

About the authors

S. I Ovcharenko

Z. N Nersesyan

References

  1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пересмотр 2006 г. (пер. с англ.) / Под ред. А.Г. Чучалина. М., 2006. 96 с.
  2. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acuteex a cerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD 2012; 9(2)131-41.
  3. Задионченко В.С. Артериальная гипертония при хронической обструктивной болезни легких. 2005. С 10-12.
  4. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-39.
  5. Палеев Н.Р., Распопина Н.А., Федорова С.И. и др. Существуетли “пульмогенная гипертензия"? // Кардиология 2002. № 6. С. 51-53.
  6. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии // Рациональная фармакотерапия в кардиологии 2009. № 4. С. 9-16.
  7. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128(4):2068- 75.
  8. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascularmortality: A population-based study and a systematic review of theliterature. Chest 2005; 12 7(6): 1952-59.
  9. Dogra S, Ardern C, Baker J. The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma 2007;44: 849-54.
  10. Suylen Rl, Smits JF, Daemen MJ. Pulmonary artery remodeling difference in hypoxia and monocrota-line induced pulmonary hypertension. Am J Respir Erit Care Med 1998; 157:1423-28.
  11. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary disease. Circulation 2001;104:263-68.
  12. Lucher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118(Suppl. ):S81 -90.
  13. Ridker P1 Cannon C, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and lnfection Therapy-hrombolysis in Myocardial Infarction 22 (PROVE lT-TlMl 22) lnvestigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
  14. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107: 1514-19.
  15. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch lntern Med. 2002;162(20):2269-76.
  16. Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31:204-12.
  17. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-107.
  18. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-69.
  19. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пересмотр 2011 г. (пер. с англ.) / Под ред. A.C. Белевского. М., 2012. 80 с.
  20. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59(7):574-80.
  21. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) // Системные гипертензии. 2010. № 3. С. 3-25.
  22. Чазова И.Е., Беленков Ю.Н., Ратова Л.Г. и др. От идеи к клинической практике. Первые результаты российского национального исследования оптимального снижения артериального давления (РОСА) // Системные гипертензии 2004. № 2. С. 18-23.
  23. Sebastian JL, McKinney WP, Kaufman J, et al. Angiotensin-converting enzyme inhibitors and cough: prevalence in an outpatient medical clinic population. Chest 1991;99:36-9.
  24. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117:234-42.
  25. Simon SR, Black HR, Moser M, et al. Cough and ACE inhibitors. Arch Intern Med 1992;152:1698-700.
  26. Simonsson BG, Skoogh BE, Bergh NP, et al. In vivo and in vitro effect of bradykinin on bronchial motor tone in normal subjects and patients with airways obstruction. Respiration 1973;30:378-88.
  27. Cascieri MA, Bull HG, Mumford RA, et al. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK422. Mol Pharmacol 1984;25:287-93.
  28. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003;123:222-43.
  29. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a doubleblind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-7.
  30. Fogari R, Fleckenstein A, Laragh JH (eds.). Hypertension - the next decade: Verapamil in focus. Churchill Livingstone, Edinburgh 1987:229-32.
  31. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Селективные-адреноблокаторы (небивалол и метопролоасукцинат) в терапии больных артериальной гипертонией и/или ишемической болезнью сердца в сочетании с бронхообструктивным синдромом: оценка эффективности и безопасности // Пульмонология 2008. № 3. С. 28-34.
  32. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Успешное применение кардиоселективного β-адреноблокатора небиволола у пациентов с арте-риальной гипертонией и/или ИБС и бронхообструктивным синдромом // Российский кардиологический журнал. 2007. № 4. С. 15-23.
  33. Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med 2010, 16:106-11.
  34. Asthma. Ed by F. Chung. EurRespir Mon 2003;8:295.
  35. Veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.
  36. Psaty B, Smith N, Siscovick D, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and metaanalysis. JAMA 1997;2 77:739-45.
  37. Ambrosioni E, Safar M, Degaute J-P, et al. Low-dose antihypertensive therapy with 1,5 mg sustained-release indapamide: results of randomized doubleblind controlled studies. European Study Group. J Hypertens 1998;16: 1677-84.
  38. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drug Saf 2001;24:1155-65.
  39. Leonetti G. Clinical positionning of indapamide sustained release 1,5 mg in management protocols for hypertension. Drugs 2000;59 (suppl. 2):27-38.
  40. Juaquerto DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-dependent production of cyclic guanosine monophosphate by bradykinin in the canine femoral artery. Am Heart J 1991;122 (2):1204-209.
  41. Necroutenko L, Agafonov A, Lykova D. Effect of Indapamide on intima-media thickness and arterial dilatation in elderly hypertensives. 12th European Meeting on Hypertension. Prague 2002.
  42. Schini VB, Dewey J, Vanhoutte PM. Indapamide potentiates the endothelium-depend relaxation in isolated canine femoral arteries. Am J Card 1990;65( 17):6H-10H.
  43. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
  44. Чазова И.Е., Мартынюк Т.В., Колос И.П. Первые результаты Российской программы СТРАТЕГИЯ у пациентов с артериальной гипертензией: оценка эффективности Нолипрела при недостаточном контроле артериального давления // Consilium medicum 2007. Т. 9. № 5. С. 5-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies